
Rasagiline
CAS No. 136236-51-6
Rasagiline( Azilect )
Catalog No. M11493 CAS No. 136236-51-6
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
10MG | 31 | In Stock |
![]() ![]() |
25MG | 50 | In Stock |
![]() ![]() |
50MG | 72 | In Stock |
![]() ![]() |
100MG | 95 | In Stock |
![]() ![]() |
200MG | 128 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameRasagiline
-
NoteResearch use only, not for human use.
-
Brief DescriptionRasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
-
DescriptionRasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.(In Vitro):Rasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment.(In Vivo):Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy.
-
In VitroRasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment. Cell Proliferation Assay Cell Line:Neuroblastoma SH-SY5Y, and glioblastoma 1242-MG Concentration:0.25 nM Incubation Time:96 hours Result:Caused ~60% increase in the cell proliferation rate for SH-SY5Y cells treated with Dexamethasone.Caused ~35% increase in cell proliferation rate for 1242-MG cells treated with Dexamethasone.
-
In VivoRasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy. Animal Model:(PLP)-α-synuclein transgenic mice over 6 months of age Dosage:Low-(0.8 mg/kg b.w.) and high dose (2.5 mg/kg b. w.) Administration:Administered subcutaneously every 24 h for a total period of 4 weeks (from day 1 till day 28 of the experiment). Result:Low dose treatment did not show protective efficacy in striatum with number of neurons similar to placebo treated MSA mice. High dose was associated with about 15% rescue of DARPP-32 immunoreactive striatal neurons.Low dose treatment had no effect on nigral neuronal loss, but high dose completely protected nigral neurons with numbers comparable to healthy controls.
-
SynonymsAzilect
-
PathwayTyrosine Kinase
-
TargetBcr-Abl
-
RecptorBcl-2| MAO-A| MAO-B
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number136236-51-6
-
Formula Weight171.24
-
Molecular FormulaC12H13N
-
Purity>98% (HPLC)
-
SolubilitySoluble in Water
-
SMILESC#CCN[C@@H]1CCc2c1cccc2
-
Chemical Name1-Indanamine, N-2-propynyl-, (R)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Naoi M, Maruyama W. Expert Rev NeurOthers. 2009 Aug;9(8):1233-50.
molnova catalog



related products
-
GNF-5
GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0.22±0.1 uM (Wild type Abl).
-
Dasatinib monohydrat...
Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML).
-
Precyasterone
Precyasterone is a natural product isolated from the dried roots of?Cyathula capitata.